Table 1 Patient characteristics including GVHD grading.
From: The effect of posttransplant cyclophosphamide on ocular graft-versus-host disease
Patient characteristics | Total | No chronic oGVHD | Chronic oGVHD | |
|---|---|---|---|---|
Demographic variable | n (%) | n (%) | n (%) | |
37 (100.0) | 22 (59.5) | 15 (40.5) | ||
Gender | ||||
Male | 23 (62.2) | 15 (68.2) | 8 (53.3) | |
Female | 14 (37.8) | 7 (31.8) | 7 (46.7) | |
Mean age (±SD) in years | 45.38 (±15.27) | 40.36 (±15.63) | 52.73 (±11.65) | |
Primary Disease | ||||
Acute lymphoblastic leukaemia (ALL) | 2 (5.4) | 1 (4.5) | 1 (4.5) | |
Acute myelogenous leukaemia (AML) | 8 (21.6) | 7 (31.8) | 1 (4.5) | |
Chronic lymphocytic leukaemia (CLL) | 6 (16.2) | 2 (9.1) | 4 (26.7) | |
Chronic myelogenous leukaemia (CML) | 3 (8.1) | 1 (4.5) | 2 (13.3) | |
Myelodysplastic syndrome (MDS) | 2 (5.4) | 0 (0.0) | 2 (13.3) | |
Lymphoma (all subtypes) | 15 (40.5) | 10 (45.5) | 5 (33.3) | |
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) | 1 (2.7) | 1 (4.5) | 0 (0.0) | |
Donor type | ||||
Related donor | 20 (54.1) | 11 (50.0) | 9 (60.0) | |
Unrelated donor | 17 (45.9) | 11 (50.0) | 6 (40.0) | |
Conditioning regimen | ||||
Fludarabine, busulfan | 22 (59.5) | 12 (54.5) | 10 (66.7) | |
Fludarabine, treosulfan | 8 (21.6) | 5 (22.7) | 3 (20.0) | |
FLAMSA, TBI 12 Gy | 3 (8.1) | 2 (9.1) | 1 (6.7) | |
Other | 4 (10.8) | 3 (13.6) | 1 (6.7) | |
GVHD prophylaxis | ||||
PT-Cy, CSA, MMF | 15 (40.5) | 10 (45.5) | 5 (33.3) | |
PT-Cy, CSA, everolimus | 1 (2.7) | 1 (4.5) | 0 (0.0) | |
PT-Cy, everolimus, MMF | 1 (2.7) | 1 (4.5) | 0 (0.0) | |
PT-Cy, tacrolimus, MMF | 5 (13.5) | 2 (9.1) | 3 (20.0) | |
PT-Cy, MMF | 1 (2.7) | 0 (0.0) | 1 (6.7) | |
PT-Cy, everolimus | 13 (35.1) | 7 (31.8) | 6 (40.0) | |
PT-Cy, everolimus, MMF, ATG | 1 (2.7) | 1 (2.7) | 0 (0.0) | |
GVHD | ||||
Acute skin GVHD | 24 (64.9) | 13 (59.1) | 11 (7.3) | |
Acute gut GVHD | 4 (10.8) | 1 (4.5) | 3 (20.0) | |
Chronic skin GVHD | 5 (13.5) | 3 (13.6) | 2 (13.3) | |
NIH grade I | 4 (10.8) | 3 (13.6) | 1 (6.7) | |
NIH grade II | 1 (2.7) | 0 (0) | 1 (6.7) | |
Chronic gut GVHD | 3 (8.1) | 2 (9.1) | 1 (6.7) | |
NIH grade I | 2 (5.4) | 2 (9.1) | 0 (0) | |
NIH grade II | 1 (2.7) | 0 (0) | 1 (6.7) | |
Non-relapse mortality | 8 (21.6) | 5 (22.7) | 3 (20.0) | |
Chronic oGVHD | ||||
NIH grading | No chronic oGVHD | Grade I | Grade II | Grade III |
n (%) | n (%) | n (%) | n (%) | |
n = 15 | 0 (0.0) | 3 (20.0) | 4 (26.7) | 8 (53.3) |
ICCGVHD | None (0–4) | Mild (5–8) | Severe (9–11) | |
n (%) | n (%) | n (%) | ||
n = 15 | 0 (0) | 10 (66.7) | 5 (33.3) | |
